Clinical Trial Update: Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating tocilizumab to prevent cytokine release syndrome after haploidentical stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Stem Cell Transplant Complications

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Cytokine Release Syndrome, Stem Cell Transplant Complications | Phase 1, Phase 2 | Status: COMPLETED